Analytical Data
-
Gene name
GDN
- Application
-
Alternative Names
GDN；PI7；PN1；Glia-derived nexin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P07093
-
Expression Region
20-398aa
-
AA Sequence
SHFNPLSLEELGSNTGIQVFNQIVKSRPHDNIVISPHGIASVLGMLQLGADGRTKKQLAMVMRYGVNGVGKILKKINKAIVSKKNKDIVTVANAVFVKNASEIEVPFVTRNKDVFQCEVRNVNFEDPASACDSINAWVKNETRDMIDNLLSPDLIDGVLTRLVLVNAVYFKGLWKSRFQPENTKKRTFVAADGKSYQVPMLAQLSVFRCGSTSAPNDLWYNFIELPYHGESISMLIALPTESSTPLSAIIPHISTKTIDSWMSIMVPKRVQVILPKFTAVAQTDLKEPLKVLGITDMFDSSKANFAKITTGSENLHVSHILQKAKIEVSEDGTKASAATTAILIARSSPPWFIVDRPFLFFIRHNPTGAVLFMGQINKP
-
Molecular Weight
57.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GDN (Glial cell line-derived neurotrophic factor) is a crucial neurotrophic factor known for its role in the survival, differentiation, and maintenance of various neuronal populations. Research into GDN has gained momentum due to its potential therapeutic implications in neurodegenerative diseases, such as Parkinson's disease, Alzheimer’s disease, and amyotrophic lateral sclerosis. Studies have demonstrated that GDN exerts protective effects on dopaminergic neurons and promotes neurogenesis, making it a target of interest for novel treatment strategies. Furthermore, GDN's ability to modulate glial cell activity highlights its significance in the neuroinflammatory response, a critical aspect in various neurological disorders. Advances in recombinant protein technology have enabled the production of GDN in a more efficient and scalable manner, facilitating extensive research into its properties and mechanisms of action. This includes exploring the optimal delivery methods for GDN in vivo, examining its interactions with specific receptors, and assessing its long-term effects on neuronal pathways. As research progresses, understanding the intricate role of GDN in neuronal health and pathology could pave the way for developing innovative therapeutic approaches aimed at alleviating the burdens of neurodegenerative diseases and enhancing neuronal repair and regeneration.
